1101 related articles for article (PubMed ID: 21976485)
1. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809.
Van Goor F; Hadida S; Grootenhuis PD; Burton B; Stack JH; Straley KS; Decker CJ; Miller M; McCartney J; Olson ER; Wine JJ; Frizzell RA; Ashlock M; Negulescu PA
Proc Natl Acad Sci U S A; 2011 Nov; 108(46):18843-8. PubMed ID: 21976485
[TBL] [Abstract][Full Text] [Related]
2. Restoration of R117H CFTR folding and function in human airway cells through combination treatment with VX-809 and VX-770.
Gentzsch M; Ren HY; Houck SA; Quinney NL; Cholon DM; Sopha P; Chaudhry IG; Das J; Dokholyan NV; Randell SH; Cyr DM
Am J Physiol Lung Cell Mol Physiol; 2016 Sep; 311(3):L550-9. PubMed ID: 27402691
[TBL] [Abstract][Full Text] [Related]
3. VX-809 corrects folding defects in cystic fibrosis transmembrane conductance regulator protein through action on membrane-spanning domain 1.
Ren HY; Grove DE; De La Rosa O; Houck SA; Sopha P; Van Goor F; Hoffman BJ; Cyr DM
Mol Biol Cell; 2013 Oct; 24(19):3016-24. PubMed ID: 23924900
[TBL] [Abstract][Full Text] [Related]
4. NBD2 Is Required for the Rescue of Mutant F508del CFTR by a Thiazole-Based Molecule: A Class II Corrector for the Multi-Drug Therapy of Cystic Fibrosis.
Brandas C; Ludovico A; Parodi A; Moran O; Millo E; Cichero E; Baroni D
Biomolecules; 2021 Sep; 11(10):. PubMed ID: 34680050
[TBL] [Abstract][Full Text] [Related]
5. Partial Rescue of F508del-CFTR Stability and Trafficking Defects by Double Corrector Treatment.
Capurro V; Tomati V; Sondo E; Renda M; Borrelli A; Pastorino C; Guidone D; Venturini A; Giraudo A; Mandrup Bertozzi S; Musante I; Bertozzi F; Bandiera T; Zara F; Galietta LJV; Pedemonte N
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34067708
[TBL] [Abstract][Full Text] [Related]
6. Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.
Veit G; Roldan A; Hancock MA; Da Fonte DF; Xu H; Hussein M; Frenkiel S; Matouk E; Velkov T; Lukacs GL
JCI Insight; 2020 Sep; 5(18):. PubMed ID: 32853178
[TBL] [Abstract][Full Text] [Related]
7. Characterization of the mechanism of action of RDR01752, a novel corrector of F508del-CFTR.
Lopes-Pacheco M; Silva IAL; Turner MJ; Carlile GW; Sondo E; Thomas DY; Pedemonte N; Hanrahan JW; Amaral MD
Biochem Pharmacol; 2020 Oct; 180():114133. PubMed ID: 32628927
[TBL] [Abstract][Full Text] [Related]
8. Measurements of Functional Responses in Human Primary Lung Cells as a Basis for Personalized Therapy for Cystic Fibrosis.
Awatade NT; Uliyakina I; Farinha CM; Clarke LA; Mendes K; Solé A; Pastor J; Ramos MM; Amaral MD
EBioMedicine; 2015; 2(2):147-53. PubMed ID: 26137539
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological Correction of Cystic Fibrosis: Molecular Mechanisms at the Plasma Membrane to Augment Mutant CFTR Function.
Arora K; Naren AP
Curr Drug Targets; 2016; 17(11):1275-81. PubMed ID: 26648081
[TBL] [Abstract][Full Text] [Related]
10. Pseudomonas aeruginosa Reduces VX-809 Stimulated F508del-CFTR Chloride Secretion by Airway Epithelial Cells.
Stanton BA; Coutermarsh B; Barnaby R; Hogan D
PLoS One; 2015; 10(5):e0127742. PubMed ID: 26018799
[TBL] [Abstract][Full Text] [Related]
11. Low free drug concentration prevents inhibition of F508del CFTR functional expression by the potentiator VX-770 (ivacaftor).
Matthes E; Goepp J; Carlile GW; Luo Y; Dejgaard K; Billet A; Robert R; Thomas DY; Hanrahan JW
Br J Pharmacol; 2016 Feb; 173(3):459-70. PubMed ID: 26492939
[TBL] [Abstract][Full Text] [Related]
12. Lipophilicity of the Cystic Fibrosis Drug, Ivacaftor (VX-770), and Its Destabilizing Effect on the Major CF-causing Mutation: F508del.
Chin S; Hung M; Won A; Wu YS; Ahmadi S; Yang D; Elmallah S; Toutah K; Hamilton CM; Young RN; Viirre RD; Yip CM; Bear CE
Mol Pharmacol; 2018 Aug; 94(2):917-925. PubMed ID: 29903751
[TBL] [Abstract][Full Text] [Related]
13. Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the F508del-CFTR mutation.
Clancy JP; Rowe SM; Accurso FJ; Aitken ML; Amin RS; Ashlock MA; Ballmann M; Boyle MP; Bronsveld I; Campbell PW; De Boeck K; Donaldson SH; Dorkin HL; Dunitz JM; Durie PR; Jain M; Leonard A; McCoy KS; Moss RB; Pilewski JM; Rosenbluth DB; Rubenstein RC; Schechter MS; Botfield M; Ordoñez CL; Spencer-Green GT; Vernillet L; Wisseh S; Yen K; Konstan MW
Thorax; 2012 Jan; 67(1):12-8. PubMed ID: 21825083
[TBL] [Abstract][Full Text] [Related]
14. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
Brewington JJ; McPhail GL; Clancy JP
Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
[TBL] [Abstract][Full Text] [Related]
15. Vx-809/Vx-770 treatment reduces inflammatory response to Pseudomonas aeruginosa in primary differentiated cystic fibrosis bronchial epithelial cells.
Ruffin M; Roussel L; Maillé É; Rousseau S; Brochiero E
Am J Physiol Lung Cell Mol Physiol; 2018 Apr; 314(4):L635-L641. PubMed ID: 29351441
[TBL] [Abstract][Full Text] [Related]
16. Correctors (specific therapies for class II CFTR mutations) for cystic fibrosis.
Southern KW; Patel S; Sinha IP; Nevitt SJ
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010966. PubMed ID: 30070364
[TBL] [Abstract][Full Text] [Related]
17. F508del-cystic fibrosis transmembrane regulator correctors for treatment of cystic fibrosis: a patent review.
Yang H; Ma T
Expert Opin Ther Pat; 2015; 25(9):991-1002. PubMed ID: 25971311
[TBL] [Abstract][Full Text] [Related]
18. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects.
Kuk K; Taylor-Cousar JL
Ther Adv Respir Dis; 2015 Dec; 9(6):313-26. PubMed ID: 26416827
[TBL] [Abstract][Full Text] [Related]
19. Novel tricyclic pyrrolo-quinolines as pharmacological correctors of the mutant CFTR chloride channel.
Renda M; Barreca M; Borrelli A; Spanò V; Montalbano A; Raimondi MV; Bivacqua R; Musante I; Scudieri P; Guidone D; Buccirossi M; Genovese M; Venturini A; Bandiera T; Barraja P; Galietta LJV
Sci Rep; 2023 May; 13(1):7604. PubMed ID: 37165082
[TBL] [Abstract][Full Text] [Related]
20. Combined effects of VX-770 and VX-809 on several functional abnormalities of F508del-CFTR channels.
Kopeikin Z; Yuksek Z; Yang HY; Bompadre SG
J Cyst Fibros; 2014 Sep; 13(5):508-14. PubMed ID: 24796242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
